HomeCompareMNKKQ vs PLD

MNKKQ vs PLD: Dividend Comparison 2026

MNKKQ yields 10000.00% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MNKKQ wins by $55137509079256504.00M in total portfolio value
10 years
MNKKQ
MNKKQ
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full MNKKQ calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — MNKKQ vs PLD

📍 MNKKQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNKKQPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNKKQ + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNKKQ pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNKKQ
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, MNKKQ beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNKKQ + PLD for your $10,000?

MNKKQ: 50%PLD: 50%
100% PLD50/50100% MNKKQ
Portfolio after 10yr
$27568754539628260.00M
Annual income
$27,036,897,836,861,447,000,000.00/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

MNKKQ
Analyst Ratings
1
Hold
2
Sell
Consensus: Sell
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNKKQ buys
0
PLD buys
0
No recent congressional trades found for MNKKQ or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNKKQPLD
Forward yield10000.00%3.10%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$55137509079256512.00M$5.91M
Annual income after 10y$54,073,795,673,722,890,000,000.00$4,750,725.19
Total dividends collected$55066727460582336.00M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusSellBuy

Year-by-year: MNKKQ vs PLD ($10,000, DRIP)

YearMNKKQ PortfolioMNKKQ Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$1,010,700$1,000,000.00$11,241$540.96+$999.5KMNKKQ
2$95,539,393$94,457,943.93$13,019$991.13+$95.53MMNKKQ
3$8,447,007,736$8,344,780,585.66$15,801$1,870.97+$8446.99MMNKKQ
4$698,565,746,383$689,527,448,105.17$20,609$3,701.21+$698565.73MMNKKQ
5$54,040,711,670,213$53,293,246,321,583.74$29,919$7,867.97+$54040711.64MMNKKQ
6$3,910,851,616,519,516$3,853,028,055,032,387.00$50,631$18,617.74+$3910851616.47MMNKKQ
7$264,781,167,546,477,440$260,596,556,316,801,570.00$105,528$51,352.20+$264781167546.37MMNKKQ
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$287,364$174,449.42+$16772556223821.38MMNKKQ
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$1,081,760$774,280.77+$994124678068809.00MMNKKQ
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$5,908,209$4,750,725.19+$55137509079256504.00MMNKKQ

MNKKQ vs PLD: Complete Analysis 2026

MNKKQStock

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Full MNKKQ Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this MNKKQ vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNKKQ vs SCHDMNKKQ vs JEPIMNKKQ vs OMNKKQ vs KOMNKKQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.